Back to Sites

St. Jude Children's Research Hospital CRS

Site Number

6501

Address

St. Jude Children's Research Hospital
262 Danny Thomas Place
Patient Care Center, 3rd Floor
Memphis, TN 38105
United States of America

IMPAACT Members at this Site

Debra Livingston CAB Liaison

Ronald Dallas Clinical Research Assistant

Robbin Christensen Co-Investigator

Judy Glenn Co-Investigator

Jennifer Griffith Co-Investigator

Nanna Howlett Co-Investigator

Susannah Keck Co-Investigator

Lennie Lott Co-Investigator

Donna Nance Co-Investigator

Nina Sublette Co-Investigator

Patricia Flynn CRS Coordinator

Jamie Russell CRS Coordinator

Jill Utech CRS Coordinator

Patricia Flynn CRS Leader

Marion Donohoe CRS Staff

Julie Maier CRS Staff

Christine Sinnock CRS Staff

Megan Loughran CTU Coordinator

Stephen Spector CTU Principal Investigator

Blanca Castillo DAIDS PO

Wally Bitar Data Manager

Aditya Gaur Investigator

Nehali Patel Investigator

Nina Sublette Investigator

Edwin Thorpe Jr. Investigator

Sherri Flax Local Laboratory

Terrence Geiger Local Laboratory

Susan Carr Pharmacist of Record

Katherine Knapp Principal Investigator

Studies at this Site

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

34150

Research Area

Treatment

Study Status

Concluded

IMPAACT 2015: Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults with Cognitive Impairment

DAIDS Number

35123

Research Area

Cure and Immunotherapy

Study Status

Concluded

IMPAACT 2018: Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/delta 1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

38405

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age

DAIDS Number

38504

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

38609

Research Area

Therapeutics

Study Status

Enrolling

IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

DAIDS Number

38637

Research Area

Therapeutics

Study Status

Enrolling

IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV

DAIDS Number

38693

Research Area

Cure and Immunotherapy

Study Status

Enrolling

IMPAACT 2017: MOCHA

DAIDS Number

30070

Research Area

Therapeutics

Study Status

Closed to Accrual

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age

DAIDS Number

38932

Research Area

Therapeutics

Study Status

Enrolling

IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1

DAIDS Number

38962

Research Area

Therapeutics

Study Status

Pending